Anja Loizaga-Velder
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Ayahuasca's potential for treating mental disorders is explored through a study at Takiwasi Center, a Peruvian facility offering an ayahuasca-assisted addiction program. The study evaluates outcomes up to 24 months
Olivia Marcus
Psychedelic-assisted therapies for adolescents are discussed, including the use of ketamine for treatment-resistant depression and the need for further studies and careful consideration of risks. Traditional use of plant medicines
Corine de Boer, Rebecca Kronman, Glauber Assis
Ibogaine, a transformative psychedelic medicine, shows promise in treating addiction by altering perception and mood. With a long history of use, it is now being tested in clinical trials.
Psilocybin therapy tested for safety, feasibility, and efficacy in cancer patients with major depressive disorder, using group treatment in a cancer center setting. Clinical trial details: NCT04593563.
Betsy Jenkins
Psychedelics and 5-HT2A agonists show varying anti-inflammatory effects unrelated to their behavioral impact. Research identifies cellular mechanisms and aims to develop new compounds with targeted therapeutic properties.
Executives of major psychedelic drug developers discuss building infrastructure for psychedelic therapy in healthcare, including education, clinics, EMR tools, and research to enhance outcomes.
Doug Drysdale
Clinicians and researchers discuss integrating psilocybin-assisted therapy into serious illness care models, presenting preliminary findings from a pilot study in hospice care for patients with terminal illness.
Yvan Beaussant, Roxanne Sholevar, Lisa Summer, Robin McKenna
MDMA-assisted therapy (MDMA-AT) shows promise in treating PTSD and comorbid eating disorders. A study found significant reductions in eating disorder symptoms with MDMA-AT compared to placebo in severe PTSD patients.
Adele LaFrance, Timothy Brewerton
Ketamine and other psychedelics show promise for psychiatric disorders, but their psychoactive effects complicate masking in trials. A triple-masked trial on 40 patients with depression found surprising results.
Boris D. Heifets
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.